drugset / Trial / NCT05397639
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Masupirdine | Small molecule | 50 mg | Oral |
| Subject | Masupirdine | Small molecule | 100 mg | Oral |